首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization
【24h】

Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization

机译:瑞格列奈基于硅酸钙的微球用于胃滞留漂浮药物的递送:制备和体外表征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Gastroretentive dosage forms have potential for use as controlled-release drug delivery systems. Multiple unit systems avoid the 'all-or-none' gastric emptying nature of single-unit systems. A controlled release system designed to increase its residence time in the stomach without contact with the mucosa was achieved through the preparation of floating microspheres by the emulsion solvent diffusion technique consisting of (i) calcium silicate (FLR) as porous carrier; (ii) repaglinide, an oral hypoglycemic agent; and (iii) Eudragit S as polymer. The effect of various formulation and process variables on the internal and external particle morphology, micromeritic properties, in vitro floating behavior, physical state of the incorporated drug, drug loading and in vitro drug release were studied. The microparticles were found to be regular in shape and highly porous. The release rate was determined in simulated gastro-intestinal fluids at 37 degrees C. The formulation demonstrated favorable in vitro floating and release characteristics. The drug encapsulation efficiency was high. Incorporation of FLR in the microspheres proved to be an effective method to achieve the desired release behavior and buoyancy. The designed system, combining excellent buoyant ability and suitable drug release pattern, could possibly be advantageous in terms of increased bioavailability of repaglinide. (c) 2005 Elsevier B.V. All rights reserved.
机译:胃滞留剂型具有用作控释药物递送系统的潜力。多单元系统避免了单单元系统的“全有或全无”胃排空特性。通过使用由乳化溶剂扩散技术制备的漂浮微球制备了一种控制释放系统,该控制释放系统旨在增加其在胃中的停留时间而不与粘膜接触,该系统由以下组成:(i)硅酸钙(FLR)作为多孔载体; (ii)瑞格列奈,口服降糖药; (iii)Eudragit S作为聚合物。研究了各种配方和工艺变量对内部和外部颗粒形态,微链性能,体外漂浮行为,掺入药物的物理状态,载药量和体外药物释放的影响。发现微粒形状规则且高度多孔。在37℃的模拟胃肠液中测定释放速率。该制剂表现出有利的体外漂浮和释放特性。药物包封效率高。在微球中掺入FLR被证明是实现所需释放行为和浮力的有效方法。设计的系统结合了出色的浮力和合适的药物释放模式,可能会增加瑞格列奈的生物利用度。 (c)2005 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号